Chinese biotech companies are lining up to list on Hong Kong’s stock exchange, despite mixed returns for the first 10 groups to take advantage of rules allowing drug developers to list on the bourse before they sell any products to patients.
中國的生物科技企業(yè)正紛紛準備在香港交易所(HKEx)上市,盡管第一批利用港交所新規(guī)上市的10家公司的回報有好有壞。該新規(guī)允許藥品開發(fā)企業(yè)在未向患者出售任何產品之前在港交所上市。
您已閱讀5%(329字),剩余95%(6583字)包含更多重要信息,訂閱以繼續(xù)探索完整內容,并享受更多專屬服務。